HR for 10-year all-cause and cardiovascular disease mortality, by HAQ at baseline and year 1
| Predictor | n | Univariate | HAQ at baseline multivariate | HAQ at year 1 multivariate |
|---|---|---|---|---|
| Adjusted for age and sex | Adjusted for ageand sex | Adjusted for age and sex | ||
| HR (95%CI) | HR (95%CI) | HR (95%CI) | ||
| ACR, American College of Rheumatology; CVD, cardiovascular disease; DAS28, Disease Activity score 28; DMARD, disease-modifying anti-rheumatic drug; HAQ, Health Assessment Questionnaire; HR, hazards ratio; RF, rheumatoid factor. | ||||
| All deaths | ||||
| HAQ at baseline (each increase of score by 1) | 1010 | 1.29 (1.05 to 1.58) | 1.22 (0.9 to 1.66) | |
| HAQ at year 1 (each increase of score by 1) | 1010 | 1.48 (1.23 to 1.77) | 1.46 (1.15 to 1.85) | |
| Change in HAQ from baseline to year 1 (adjusted for baseline HAQ) | ||||
| Reduction in HAQ score from baseline to year 1 | 505 | 10 | ||
| No change in HAQ score from baseline to year 1 | 182 | 1.37 (0.87 to 2.17) | ||
| Increase in HAQ score from baseline to year 1 | 323 | 1.33 (0.95 to 1.87) | ||
| Swollen and tender joint count at baseline (each increase in count by 1) | 1010 | 1.00 (0.98 to 1.02) | ||
| Swollen and tender joint count at year 1 (each increase in count by 1) | 1005 | 0.99 (0.96 to 1.02) | ||
| RF positive (RF titre ⩾1:80) at baseline | 891 | 1.49 (1.05 to 2.11) | 1.56 (1.07 to 2.26) | 1.45 (0.99 to 2.1) |
| Satisfy ACR criteria at baseline | 1010 | 0.95 (0.7 to 1.29) | ||
| DAS28 score at baseline (each increase of score by 1) | 795 | 1.15 (1.02 to 1.3) | 1.04 (0.89 to 1.22) | 1.02 (0.89 to 1.17) |
| Treated with DMARD by first year | 1010 | 1.41 (1.02 to 1.93) | 1.37 (0.92 to 2.02) | 1.37 (0.93 to 2.03) |
| Deaths due to CVD | ||||
| HAQ at baseline (each increase of score by 1) | 928 | 1.22 (0.92 to 1.63) | 1.12 (0.82 to 1.54) | |
| HAQ at year 1 (each increase of score by 1) | 928 | 1.60 (1.24 to 2.06) | 1.49 (1.12 to 1.97) | |
| Change in HAQ from baseline to year 1 (adjusted for baseline HAQ) | ||||
| Reduction in HAQ score from baseline to year 1 | 466 | 1 | ||
| No change in HAQ core from baseline to year 1 | 167 | 1.17 (0.59 to 2.31) | ||
| Increase in HAQ score from baseline to year 1 | 295 | 1.47 (0.93 to 2.34) | ||
| Swollen and tender joint count at baseline (each increase in count by 1) | 928 | 0.99 (0.96 to 1.02) | ||
| Swollen and tender joint count at year 1 (each increase in count by 1) | 923 | 0.98 (0.93 to 1.02) | ||
| RF-positive (RF titre ⩾1:80) at baseline | 825 | 2.21 (1.41 to 3.47) | 1.99 (1.25 to 3.17) | 1.87 (1.18 to 2.98) |
| Satisfy ACR criteria at baseline | 928 | 0.86 (0.56 to 1.32) | ||
| DAS28 score at baseline (each increase of score by 1) | 737 | 1.12 (0.95 to 1.33) | ||
| Treated with DMARD by first year | 928 | 1.60 (1.03 to 2.48) | 1.48 (0.9 to 2.45) | 1.44 (0.88 to 2.36) |